1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Transcenta Holding Limited

Transcenta Holding Limited

6628.HK
Transcenta Holding LimitedHK flagHong Kong Stock Exchange
1.07
HKD
- -
- -
456.03MMarket Cap
Transcenta Holding Limited
6628.HK
(Hong Kong Stock Exchange)

Recent

price

1.07

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
FRC
0.1
0.18
0.27
0.24
0.13
0.03
- -
Revenue per Share
-0.89
-0.71
-9.34
-0.94
-1.14
-0.72
- -
Basic EPS, GAAP
-1.04
-0.53
-2.49
-0.73
-0.92
-0.53
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
-7.04
-8.62
-9.39
- -
Book Value per Share
-2.7
-3.11
7.61
2.09
1.13
0.45
- -
Tangible Book Value per Share
445
445
184
433
407
405
- -
Basic Weighted Avg Shares
44
81
50
102
54
11
7
Sales/Revenue/Turnover
-739.1
-419.3
-1,002.84
-413.83
-861.5
-2,169.37
-2,461.41
Operating Margin (%)
41
42
52
55
54
52
49
Depreciation Expense
-395
-317
-1,716
-407
-463
-290
-204
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-895.46
-390.99
-3,414.56
-399.19
-859.01
-2,577.85
-2,740.08
Profit Margin (%)
338
697
970
506
130
-63
-160
Working Capital
176
155
85
19
28
31
17
LT Debt
-636
-816
1,966
1,474
1,028
752
618
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-575,683.64
-961,088.52
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-88.15%
-17.77%
Free Cash Flow
- -
0.71%
-33.85%
Net Income, GAAP
- -
62.44%
-29.82%
Sales/Revenue/Turnover
- -
-19.08%
-33.98%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
54
2024
- -
- -
- -
- -
11
2025
- -
- -
- -
- -
7

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-1.14
2024
- -
- -
- -
- -
-0.72
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Keymed Biosciences Inc. (2162.HK)
Korro Bio, Inc. (KRRO)
Vertex Pharmaceuticals Incorporated (0QZU.L)
GenVec, Inc. (GNVC)
MaxCyte, Inc. (MXCT)
OBI Pharma, Inc. (4174.TWO)
Business
Transcenta Holding Limited (6628.HK) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based and antibody-drug conjugate therapeutics targeting difficult-to-treat solid tumors. The company offers a pipeline of product candidates including TST001, a PD-L1 x VEGF bispecific antibody; TST002, a Claudin18.2 antibody-drug conjugate; TST003, an anti-TL1A antibody; and others such as TST004 (EGFR antibody), TST005 (ROR1 antibody), and TST009 (DR5 x TLR9 bispecific antibody), primarily through its proprietary Transcenta Antibody Discovery System (TADS) platform and Hua Medicine diabetes pipeline assets. Transcenta operates in the oncology and metabolic disease segments, targeting unmet needs in solid tumors and type 2 diabetes with customers including pharmaceutical partners and clinical trial participants across Asia, North America, and Europe; it was founded in 2018 and is headquartered in Suzhou, China, with additional facilities in Hefei, China, and Rockville, Maryland, USA. Recently, in 2024, Transcenta completed a strategic business combination with Cartesian Therapeutics, adopting the new name Cartesian Therapeutics, Inc. (NASDAQ: RNAC), which expanded its pipeline into autoimmune diseases while retaining its oncology focus; this followed the delisting from the Hong Kong Stock Exchange and marked a major reorganization including leadership transitions and integration of Hua Medicine's diabetes assets. The company also advanced multiple clinical trials, such as Phase II for TST001 in gastric cancer and partnerships for global development rights.

Company News

APIChatGPT

  • headlinesoftoday.com

    Transcenta Holding Limited (6628.HK) to Hold 2023 ASCO Business Update call Conference.